Ausgabe 4/2023
Inhalt (18 Artikel)
ASCO 2023—partnering with patients: the cornerstone of cancer care and research
Gabriel Rinnerthaler
Essential news from ASCO 2023 in primary resectable and advanced or metastatic pancreatic cancer
Patrick Reimann, Thomas Winder
ASCO update—hepatocellular carcinoma and cholangiocellular carcinoma
Angela Djanani
Second-line treatment of HER2-positive advanced gastroesophageal adenocarcinoma
Aysegül Ilhan-Mutlu, Ewald Wöll
Fifth-line HER2-directed therapy for metastatic adenocarcinoma of the gastroesophageal junction
Sophie Roider-Schur, Sybille Machat, Leopold Öhler
Comment to Smith MR, Hussain M, Saad F et al. (2022, N Engl J Med) Darolutamide and survival in metastatic, hormone-sensitive prostate cancer
Isabel Heidegger, Andreas Pircher
Focal therapy in intermediate- and high-risk prostate cancer
Nicolai A. Huebner, Stephan Korn, Pawel Rajwa, Shahrokh F. Shariat
Imaging and therapy targeting PSMA receptors for enhanced vision and precise treatment
Sazan Rasul, Stephan Korn
Challenges in prevention, early detection, and management of febrile neutropenia in adult patients with solid tumors
Petar Popov
Erythropoiesis-stimulating agents—benefits and harms in the treatment of anemia in cancer patients
Ronald Heregger, Richard Greil
Management of malignant hypercalcemia in cancer patients—a short review
Clemens Petrasch, Petra Marics, Thomas Spanberger
WNT3 and LEF1 as markers for diagnosis and survival prediction in chronic lymphocytic leukemia patients
Manal Atef, Layla M. Saleh, Noha Eisa, Sameh Shamaa